Cover Image

Engineering of Stimulus-Responsive Pirfenidone Liposomes for Pulmonary Delivery During Treatment of Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease characterized by progressive and irreversible loss of lung function. Clinically safe and efficacious drug treatments for IPF are lacking. Pirfenidone (an anti-inflammatory, antioxidant and anti-fibrotic small-molecule drug) is consi...

Full description

Saved in:

Bibliographic Details
Main Authors:	Meishan Han (Author), Yingjian Song (Author), Sha Liu (Author), Xiaoyan Lu (Author), Linyu Su (Author), Meixuan Liu (Author), Xiaosu Zhu (Author), Kaoxiang Sun (Author), Yanan Lu (Author), Aiping Wang (Author)
Format:	Book
Published:	Frontiers Media S.A., 2022-04-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Pirfenidone treatment of idiopathic pulmonary fibrosis
by: Ye Gan, et al.
Published: (2011)

Effects and mechanisms of pirfenidone, prednisone and acetylcysteine on pulmonary fibrosis in rat idiopathic pulmonary fibrosis models
by: Wencheng Yu, et al.
Published: (2017)

Preparation and evaluation of pirfenidone loaded chitosan nanoparticles pulmonary delivery for idiopathic pulmonary fibrosis
by: Kiran Dudhat, et al.
Published: (2022)

Role of pirfenidone in the management of pulmonary fibrosis
by: Meyer KC, et al.
Published: (2017)

Differences in tolerability of pirfenidone between elderly and younger patients with idiopathic pulmonary fibrosis
by: Sakayori M, et al.
Published: (2019)

Efficacy and safety of combination therapy with pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis
by: Jin-Young Huh, et al.
Published: (2023)

Pirfenidone and Nintedanib in Pulmonary Fibrosis: Lights and Shadows
by: Maria Chianese, et al.
Published: (2024)

Effectiveness of Pharmacist-Physician Collaborative Management for Patients With Idiopathic Pulmonary Fibrosis Receiving Pirfenidone
by: Yukari Satsuma, et al.
Published: (2020)

Analysis of the safety and efficacy of different plasma concentrations of pirfenidone in patients with idiopathic pulmonary fibrosis
by: Hui Li, et al.
Published: (2022)

Cost-effectiveness of pirfenidone compared to all available strategies for the treatment of idiopathic pulmonary fibrosis in France
by: Emilie Clay, et al.
Published: (2019)

Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic
by: José M. Serra López-Matencio, et al.
Published: (2021)

South-West of England's Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
by: Shaney L. Barratt, et al.
Published: (2018)

The role of nintedanib and pirfenidone in the treatment of idiopathic pulmonary fibrosis and review of recent clinical trials of IPF therapy
by: Michał Żuber, et al.
Published: (2024)

Efficient transfected liposomes co-loaded with pNrf2 and pirfenidone improves safe delivery for enhanced pulmonary fibrosis reversion
by: Xin Chang, et al.
Published: (2023)

Pirfenidone in Idiopathic Pulmonary Fibrosis: Real-World Observation on Efficacy and Safety, Focus on Patients Undergoing Antithrombotic and Anticoagulant
by: Nicolò Reccardini, et al.
Published: (2024)

Repurposing of Pirfenidone (Anti-Pulmonary Fibrosis Drug) for Treatment of Rheumatoid Arthritis
by: Donghao Gan, et al.
Published: (2021)

Effects of Pirfenidone and Nintedanib on Markers of Systemic Oxidative Stress and Inflammation in Patients with Idiopathic Pulmonary Fibrosis: A Preliminary Report
by: Alessandro G. Fois, et al.
Published: (2020)

Pulmonary delivery of liposomal dry powder inhaler formulation for effective treatment of idiopathic pulmonary fibrosis
by: S. Chennakesavulu, et al.
Published: (2018)

Idiopathic Pulmonary Fibrosis
Published: (2022)

Idiopathic Pulmonary Fibrosis: An Update on Pathogenesis
by: Qianru Mei, et al.
Published: (2022)

Management of Pulmonary Hypertension in Idiopathic Pulmonary Fibrosis
by: Abdullah Rashed Alharbi
Published: (2024)

Post-inflammatory pulmonary fibrosis in a discharged COVID-19 patient: Effectively treated with Pirfenidone
by: Zhan Xi, et al.
Published: (2020)

Cough in Idiopathic Pulmonary Fibrosis
by: Jennifer Mann, et al.
Published: (2021)

Risk of potential hepatotoxicity from pirfenidone or nintedanib in patients with idiopathic pulmonary fibrosis: results of a retrospective analysis of a large insurance database in Taiwan
by: Kuang-Ming Liao, et al.
Published: (2024)

Salvianolic acid B dry powder inhaler for the treatment of idiopathic pulmonary fibrosis
by: Peng Lu, et al.
Published: (2022)

The Role of DNA Damage and Repair in Idiopathic Pulmonary Fibrosis
by: Jiahui Zhu, et al.
Published: (2022)

Clinical, radiological, and serological assessment of the efficacy and safety of nintedanib compared to pirfenidone in a sample of Iraqi patients with idiopathic pulmonary fibrosis: A retrospective cohort study
by: Walaa Abdul Jabbar Al-Sarraf, et al.
Published: (2024)

State of the Art in Idiopathic Pulmonary Fibrosis
Published: (2023)

Prospects for Treatment of Idiopathic Pulmonary Fibrosis
by: R. N. Mustafin
Published: (2022)

Aerosol Delivery of Surfactant Liposomes for Management of Pulmonary Fibrosis: An Approach Supporting Pulmonary Mechanics
by: Sabna Kotta, et al.
Published: (2021)

Pirfenidone Inhibits Hypoxic Pulmonary Hypertension through the NADPH/ROS/p38 Pathway in Adventitial Fibroblasts in the Pulmonary Artery
by: Song Zhang, et al.
Published: (2020)

Maimendong Decoction Improves Pulmonary Function in Rats With Idiopathic Pulmonary Fibrosis by Inhibiting Endoplasmic Reticulum Stress in AECIIs
by: Mengmeng Shen, et al.
Published: (2020)

Idiopathic pulmonary fibrosis and GERD: links and risks
by: Ghisa M, et al.
Published: (2019)

The epithelium in idiopathic pulmonary fibrosis: breaking the barrier
by: Ana eCamelo, et al.
Published: (2014)

Small airway dysfunction in idiopathic pulmonary fibrosis
by: Chengsheng Yin, et al.
Published: (2022)

Update on therapeutic management of idiopathic pulmonary fibrosis
by: Tzouvelekis A, et al.
Published: (2015)

Pharmacokinetics and tissue distribution of bleomycin-induced idiopathic pulmonary fibrosis rats treated with cryptotanshinone
by: Xiangjun He, et al.
Published: (2023)

The Role of Infection in Acute Exacerbation of Idiopathic Pulmonary Fibrosis
by: Dong Weng, et al.
Published: (2019)

Treatment of pulmonary hypertension in idiopathic pulmonary fibrosis: shortfall in efficacy or trial design?
by: Nathan SD, et al.
Published: (2014)

Feasibility and Mechanism Analysis of Shenfu Injection in the Treatment of Idiopathic Pulmonary Fibrosis
by: Peipei Liu, et al.
Published: (2021)